• Mashup Score: 0
    Publications Lounge | ASCO Annual Meeting - 11 month(s) ago

    Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with…

    Source: conferences.asco.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      .@ASCO journal authors, reviewers, editors & Editorial Board members are welcome to join us in the #ASCO23 Publications Lounge (S403b), today from 8 AM to 5 PM (CT), for programming, networking, and a quiet place to relax or catch up. ☕ https://t.co/J1SzLryJC4 https://t.co/uE4PPIay6A

  • Mashup Score: 0
    Publications Lounge | ASCO Annual Meeting - 11 month(s) ago

    Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with…

    Source: conferences.asco.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      .@ASCO journal authors, reviewers, editors & Editorial Board members are welcome to join us in the #ASCO23 Publications Lounge (S403b), 8 AM to 5 PM (CT), Saturday, Sunday & Monday, for programming, networking & a quiet place to relax or catch up. ☕ https://t.co/BmZMdzvXX6 https://t.co/zhUvdJ9cDT

  • Mashup Score: 0
    ASCO 2023 Publications Lounge Mentoring - 11 month(s) ago

    Please review the available slots below and click on the button to sign up (all times shown in Central Time). You may sign up for one 25-minute mentoring slot. You can review a brief summary of each mentor’s interests and expertise via the PDF file below. Questions? Contact pubs@asco.org.

    Source: www.signupgenius.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      Last call! ⌚ Early career? Interested in publishing? 🤝 Register for one-on-one mentoring in the ASCO Publications Lounge at #ASCO23! Sign up closes 11:59pm ET TODAY May 26. ➡️ https://t.co/QRGKTjZpZ0

  • Mashup Score: 0
    Optimizing and Refining Immunotherapy in Breast Cancer - 1 year(s) ago

    Despite a rocky start in breast cancer, immune checkpoint inhibitors (ICIs) have now made their way into clinical practice.1 As noted in the review article accompanying this commentary by Jacob et al2 titled Role of Immunotherapy in Breast Cancer, the journey in developing immunotherapy in breast cancer has been challenging. Indeed, we have observed mostly low response rates to single-agent ICIs,…

    Source: JCO Oncology Practice
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      #JCOOP #BCSM Commentary by Dr. Cesar Santa-Maria: "Where do we go from here with #immunotherapy in #breastcancer? Our foot is in the door...but we need better methods of identifying who actually benefits from ICIs & also understand resistance better" ➡️ https://t.co/yL0pHlxnKc

  • Mashup Score: 0
    Role of Immunotherapy in Breast Cancer - 1 year(s) ago

    The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust data to date for ICI exist for triple-negative breast cancer (TNBC). Preclinical studies suggested increased antitumoral immune response in patients with TNBC undergoing ICI treatment. Early clinical trials investigated the…

    Source: JCO Oncology Practice
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      #Immunotherapy in #BreastCancer review @SayaJacob3: ICIs have efficacy when combined with chemo in the tx of #TNBC but important questions remain including optimal partners for #ICI, duration, predictive biomarkers, and use for HR+ and HER2+ 👉 https://t.co/F48XRYYxkb #bcsm https://t.co/7N2Ew96L9C

  • Mashup Score: 0
    JCO Oncology Practice: Vol 19, No 1 - 1 year(s) ago

    FROM THE EDITOR’S DESKSPECIAL SERIES: TEAMS IN CANCER CAREEDITORIALSCLINICAL REVIEWSCommentariesSPECIAL SERIES: TEAMS IN CANCER CAREQUALITY IN ACTIONFocus on QualitySPECIAL SERIES: TEAMS IN CANCER CAREMORBIDITY, MORTALITY AND IMPROVEMENT ROUNDSGUIDELINE SUMMARIESFocus on QualitySPECIAL SERIES: TEAMS IN CANCER CAREORIGINAL CONTRIBUTIONS

    Source: JCO Oncology Practice
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCOOP_ASCO
      JCOOP_ASCO

      What is team-based cancer care and how has it evolved over the past decade? This new #JCOOP special series highlights transformations in team-based delivery models within the cancer care system and their potential direction. ➡️ https://t.co/MjAfmNnPRQ #onctwitter #TeamBasedCare

Load More